(Q34212503)

31 July 2017

1 reference

title

The therapeutic potential of cannabis (English)

1 reference

31 July 2017

3

Gavin Giovannoni

1 reference

31 July 2017

David Baker

1

1 reference

31 July 2017

Gareth Pryce

series ordinal

2

1 reference

31 July 2017

Alan J Thompson

series ordinal

4

1 reference

31 July 2017

publication date

1 May 2003

1 reference

31 July 2017

1 reference

31 July 2017

volume

2

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

291-298

1 reference

The perceived effects of smoked cannabis on patients with multiple sclerosis

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Cannabinoids and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Pharmacological actions and therapeutic uses of cannabis and cannabinoids.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Effects of cannabidiol in animal models predictive of antipsychotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Molecular characterization of a peripheral receptor for cannabinoids

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Molecular biology of cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Pharmacology of cannabinoid CB1 and CB2 receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Endocannabinoids and related fatty acid derivatives in pain modulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Cardiovascular pharmacology of anandamide

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

The fatty acid amide hydrolase (FAAH)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Endocannabinoid signaling in the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Dopamine activation of endogenous cannabinoid signaling in dorsal striatum

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Cannabis and psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Cannabis use and psychosis: a longitudinal population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

The endogenous cannabinoid system controls extinction of aversive memories

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Cannabinoid analgesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Control of pain initiation by endogenous cannabinoids.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Cannabinoids control spasticity and tremor in a multiple sclerosis model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Endocannabinoids control spasticity in a multiple sclerosis model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Endocannabinoids in pain modulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Intravesical treatment of overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

CB(1) receptor antagonist SR141716A increases capsaicin-evoked release of Substance P from the adult mouse spinal cord

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Bypassing the first-pass effect for the therapeutic use of cannabinoids

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

The therapeutic potential of the cannabinoids in neuroprotection

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

An endogenous cannabinoid (2-AG) is neuroprotective after brain injury

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Brain cannabinoid systems as targets for the therapy of neurological disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Neuroprotective Antioxidants from Marijuanaa

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

[Some practice-relevant aspects of the pharmacokinetics of THC]

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Evaluation of intramuscular levonantradol and placebo in acute postoperative pain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Modulation of anxiety through blockade of anandamide hydrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Bidirectional control of airway responsiveness by endogenous cannabinoids

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Cannabinoids in the treatment of glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Ajulemic acid (CT3): a potent analog of the acid metabolites of THC.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

New cannabinoid for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

Cannabinoids in MS: potentially useful but not just yet!

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

[Results of a standardized survey on the medical use of cannabis products in the German-speaking area].

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900381-8

7 January 2021

10.1016/S1474-4422(03)00381-8

Identifiers

DOI

1 reference

31 July 2017

1 reference